Published in Invest Ophthalmol Vis Sci on March 01, 2008
Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23~27~24 clusters. Proc Natl Acad Sci U S A (2011) 2.10
Animal models of age related macular degeneration. Mol Aspects Med (2012) 1.39
Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci (2011) 1.23
Neuroprotectin D1 attenuates laser-induced choroidal neovascularization in mouse. Mol Vis (2010) 1.06
Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets. Br J Pharmacol (2012) 1.06
Suppression and regression of choroidal neovascularization in mice by a novel CCR2 antagonist, INCB3344. PLoS One (2011) 1.01
VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV. PLoS One (2013) 1.01
The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization. Mol Immunol (2011) 0.98
Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization. J Ocul Pharmacol Ther (2012) 0.96
Improved assessment of laser-induced choroidal neovascularization. Microvasc Res (2010) 0.95
Oxidative stress sensitizes retinal pigmented epithelial (RPE) cells to complement-mediated injury in a natural antibody-, lectin pathway-, and phospholipid epitope-dependent manner. J Biol Chem (2013) 0.92
VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2. Angiogenesis (2014) 0.91
In-vivo investigation of laser-induced choroidal neovascularization in rat using spectral-domain optical coherence tomography (SD-OCT). Graefes Arch Clin Exp Ophthalmol (2012) 0.83
Local production of the alternative pathway component factor B is sufficient to promote laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci (2015) 0.81
Hypoxia-regulated retinal glial cell-specific promoter for potential gene therapy in disease. Invest Ophthalmol Vis Sci (2011) 0.81
Aurintricarboxylic acid inhibits complement activation, membrane attack complex, and choroidal neovascularization in a model of macular degeneration. Invest Ophthalmol Vis Sci (2013) 0.81
An angiogenic role for adrenomedullin in choroidal neovascularization. PLoS One (2013) 0.80
A Simple Optical Coherence Tomography Quantification Method for Choroidal Neovascularization. J Ocul Pharmacol Ther (2015) 0.80
Effects of Docosahexaenoic Acid in Preventing Experimental Choroidal Neovascularization in Rodents. J Clin Exp Ophthalmol (2011) 0.79
Phosphatidylserine (PS) Is Exposed in Choroidal Neovascular Endothelium: PS-Targeting Antibodies Inhibit Choroidal Angiogenesis In Vivo and Ex Vivo. Invest Ophthalmol Vis Sci (2015) 0.77
Rac1 activates HIF-1 in laser induced choroidal neovascularization. Int J Ophthalmol (2011) 0.77
Increased VEGF-A promotes multiple distinct aging diseases of the eye through shared pathomechanisms. EMBO Mol Med (2016) 0.76
An angiotensin-converting enzyme inhibitor modulates stromal-derived factor-1 through CD26/dipeptidyl peptidase IV to inhibit laser-induced choroidal neovascularization. Mol Vis (2013) 0.75
A Sema3C Mutant Resistant to Cleavage by Furin (FR-Sema3C) Inhibits Choroidal Neovascularization. PLoS One (2016) 0.75
A Quantitative and Standardized Method for the Evaluation of Choroidal Neovascularization Using MICRON III Fluorescein Angiograms in Rats. PLoS One (2015) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Cryopyrin activates the inflammasome in response to toxins and ATP. Nature (2006) 18.74
Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature (2004) 14.80
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature (2006) 13.75
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell (2003) 9.12
Non-canonical inflammasome activation targets caspase-11. Nature (2011) 8.85
Autocrine VEGF signaling is required for vascular homeostasis. Cell (2007) 7.37
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature (2006) 6.56
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 6.44
Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science (2013) 5.06
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science (2003) 4.56
Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A (2002) 4.46
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature (2002) 4.10
The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell (2003) 3.89
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science (2009) 3.87
Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol (2009) 3.85
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell (2009) 3.71
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem (2005) 3.30
Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell (2004) 3.28
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell (2002) 3.27
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol (2010) 3.15
The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation. Dev Cell (2006) 3.10
A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol (2010) 3.09
The molecular basis of vascular lumen formation in the developing mouse aorta. Dev Cell (2009) 3.08
The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol (2007) 3.06
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol (2005) 3.00
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res (2005) 3.00
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med (2013) 3.00
The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature (2004) 2.95
Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 2.93
Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol (2011) 2.83
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A (2010) 2.77
Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res (2006) 2.75
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A (2009) 2.68
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell (2010) 2.64
Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest (2012) 2.58
Role of VEGF-A in vascularization of pancreatic islets. Curr Biol (2003) 2.56
VEGFA is necessary for chondrocyte survival during bone development. Development (2004) 2.54
TSPAN12 regulates retinal vascular development by promoting Norrin- but not Wnt-induced FZD4/beta-catenin signaling. Cell (2009) 2.53
EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development (2007) 2.45
CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair. Blood (2012) 2.43
Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med (2009) 2.42
Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol (2005) 2.38
Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell (2008) 2.35
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res (2008) 2.33
Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A (2008) 2.30
Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev Biol (2003) 2.24
VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J (2004) 2.22
Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J (2012) 2.21
The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res (2012) 2.19
In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J Clin Invest (2007) 2.18
High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol (2004) 2.14
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell (2011) 2.14
Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol (2006) 2.10
Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res (2008) 2.08
ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J Biol Chem (2002) 2.02
IgE⁺ memory B cells and plasma cells generated through a germinal-center pathway. Nat Immunol (2012) 2.00
A direct and melanopsin-dependent fetal light response regulates mouse eye development. Nature (2013) 1.98
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol (2010) 1.94
Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback. Development (2005) 1.93
Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature (2011) 1.91
Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest (2012) 1.90
Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell (2012) 1.79
The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. Proc Natl Acad Sci U S A (2003) 1.78
VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res (2008) 1.76
PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell (2010) 1.75
Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc Natl Acad Sci U S A (2004) 1.75
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A (2007) 1.73
Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol (2010) 1.72
Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev Cell (2009) 1.72
Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation (2004) 1.71
Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol (2010) 1.70
Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol (2005) 1.64
Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology (2012) 1.63
Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci (2008) 1.63
Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood (2004) 1.62
Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci (2009) 1.58
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res (2011) 1.56
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res (2009) 1.56
Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb Haemost (2004) 1.55
The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med (Berl) (2002) 1.54
Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J Mol Biol (2004) 1.53
Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis. Dev Biol (2007) 1.51
Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol (2008) 1.51
An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe (2013) 1.46